Reboot Rx advances affordable cancer treatments by repurposing generic drugs.
We work where commercial incentives don’t.
Independent nonprofit · Evidence-based · Powered by AI
The Problem We’re Solving
Some existing generic drugs show strong evidence for cancer treatment, but the system is not designed to move low-cost, off-patent options forward.
Reboot Rx identifies and helps move forward new uses for FDA-approved generic drugs with evidence for cancer treatment, which are rarely advanced through traditional commercial pathways once patents expire.
As an independent nonprofit, we provide unbiased information to healthcare decision-makers on treatments that may be added to the standard care. Reboot Rx does not manufacture or sell drugs, and does not profit from the sale of drugs.
What We Do
IDENTIFY
Aggregate public clinical evidence to surface generic drugs with strong data and potential impact in cancer care.
INVESTIGATE
Evaluate the evidence, and, where appropriate, support additional research through partnerships.
INFORM
Share clear, synthesized findings with clinicians and health systems to support decision-making in patient care.
Progress & Path Forward
Our analysis has already yielded high-potential repurposing opportunities from an ever-growing list of generic medicines.
Who We Work With
CLINICIANS • RESEARCHERS • HEALTH SYSTEMS • DONORS
Our Story
Many of us at Reboot Rx have been personally affected by cancer. That experience fuels our urgency and our commitment to repurposing generic drugs to improve the lives of cancer patients.
Founder Laura Kleiman with her mother
